5 recruiting, 4 not yet recruiting, 2 completed, 1 active not recruiting. 7 Phase 2, 3 Phase 1, 1 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Acral Melanoma: new trials by email Literature Review of Acral Melanoma trials Research Report on Acral Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma Wide Local Excision - Cutaneous Melanoma, Stage II, Cutaneous Melanoma | Not applicable | Not yet recruiting | University of Nebraska | 282 | 2026-12-24 | 2026-10-09 |
| A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus) - Melanoma, Acral Melanoma | Phase 4 | Not yet recruiting | Peking University Cancer Hospital & Institute | 76 | 2026-10-01 | 2026-10-02 |
| Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma Iparomlimab and Tuvoraleimab injection+Bev+nab-PC - Acral Melanoma, Mucosal Melanoma | Phase 2 | Not yet recruiting | Fudan University | 48 | 2026-02-01 | 2026-01-16 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial Toripalimab combined with Endostar - Melanoma of Skin, Acral Melanoma | Phase 2 | Recruiting | Fudan University | 58 | 2025-01-01 | 2025-05-11 |
| An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions. Skin Cancers - Basal Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma | Not yet recruiting | University of Auckland, New Zealand | 3000 | 2024-12-13 | 2024-10-28 | |
| Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab - Acral Melanoma | Phase 3 | Recruiting | Peking University Cancer Hospital & Institute | 140 | 2023-03-21 | 2023-09-06 |
| Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor Pembrolizumab, Vactosertib - Acral Melanoma, Mucosal Melanoma | Phase 2 | Terminated | Yonsei University | 14 | 2023-02-09 | 2025-04-02 |
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma TBio-4101, Cyclophosphamide, Fludarabine - Metastatic Melanoma, Unresectable Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2022-11-22 | 2026-04-02 |
| Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma Camrelizumab - Melanoma, Acral Melanoma | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2022-09-13 | 2025-03-03 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma SHR-1210+Apatinib - Acral Melanoma | Phase 2 | Recruiting | Di Wu | 40 | 2021-03-01 | 2021-05-26 |
| Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Nilotinib - Mucosal Lentiginous Melanoma, Acral Melanoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 20 | 2009-01-23 | 2018-11-15 |
Melanoma (9) · Carcinoma, Basal Cell (2) · Neoplasm Metastasis (2) · Skin Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Uveal Melanoma (2) · Adenocarcinoma of Lung (1) · Adenoma, Islet Cell (1) · Adrenocortical Carcinoma (1) · Breast Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1)
Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Nerve Tissue (9) · Neuroectodermal Tumors (9) · Nevi and Melanomas (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Neoplasms (8) · Neuroendocrine Tumors (8) · Skin Neoplasms (7) · Carcinoma (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Adenoma (2)
Cyclophosphamide (2) · Interleukin-2 (2) · camrelizumab (2) · fludarabine phosphate (2) · pembrolizumab (2) · Biopsy (1) · Fluorodeoxyglucose F18 (1) · Interleukin-13 (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Temozolomide (1) · apatinib (1) · endostar protein (1) · fludarabine (1) · nilotinib (1)
Peking University Cancer Hospital & Institute (3) · Fudan University (2) · Anusha Kalbasi (1) · Dana-Farber Cancer Institute (1) · Di Wu (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Medicenna Therapeutics, Inc. (1) · University of Auckland, New Zealand (1) · University of Nebraska (1) · Yonsei University (1)
China (5) · United States (5) · South Korea (2) · Australia (1) · Canada (1) · Ireland (1) · New Zealand (1) · Portugal (1) · Spain (1) · Switzerland (1)
Allison Betof Warner, MD, PhD (1) · Amod Sarnaik, MD (1) · Antoni Ribas, MD, PhD (1) · Arash Yavari, MBBS (1) · Chunmeng Wang, Dr. (1) · F. Stephen Hodi, MD (1) · Joshua Mammen (1) · Jun Guo (1) · Jun Guo, Dr (1) · Michel K Nieuwoudt, PhD (1) · Minkyu Jung (1) · Nina Merchant (1) · Yan Xing, MD, PhD (1)
2023 (1)